A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

Trial Details

NCT ID
NCT06110793
Phase
PHASE1 / PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Lenvatinib
  • Pembrolizuma
  • Fulvestrant
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Male or female participants who are ≥18 years old with histologically confirmed diagnosis of unresectable locally advanced or MBC.
  • Male participants or premenopausal females are eligible as long as they are on LHRH agonist for at least four weeks prior to starting trial therapy…
  • Patients diagnosed with ER+ (ER \>1%), HER2- breast cancer as per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CA…
  • Progressed on at least 1 prior endocrine therapy combined with CDK 4/6 inhibitor. Prior fulvestrant therapy is permitted.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →